Is Benzodiazepine Use Associated with the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: The use of benzodiazepines in relation to cognitive decline remains an area of controversy in aging populations. Objective: This study aims to evaluate the risk of cognitive impairment–not dementia (CIND), Alzheimer disease (AD), and all-cause dementia with benzodiazepine use. The effect modification by sex was also investigated. Methods: Data come from the Canadian Study of Health and Aging, a 10-year multicentric study involving 10 263 participants randomly selected, 65 years and older, living in the community and in institutions. Current exposure to benzodiazepines was assessed in a face-to-face interview or self-reported in a questionnaire. Cox proportional hazard regression models, using age as time scale, were conducted to estimate hazard ratios, with adjustment for sex, education, smoking, alcohol intake, depression, physical activity, nonsteroidal anti-inflammatory drug use, and vascular comorbidities. Results: Data sets included 5281 participants for dementia as the outcome, 5015 for AD, and 4187 for CIND. Compared with nonusers, current use of benzodiazepines was associated with an increased risk of CIND (hazard ratio = 1.36; 95% CI = 1.08-1.72) in the simplest model. Results remained similar in the fully adjusted model (hazard ratio = 1.32; 95% CI = 1.04-1.68). There was no association between benzodiazepine use and the risk of dementia or AD. All these effects were similar between men and women. Conclusion and Relevance: Benzodiazepine use in older people from the general population is related to subsequent occurrence of cognitive dysfunction but not implicated in the pathogenesis of dementia or AD. Caution should be exercised when prescribing benzodiazepines to preserve global cognitive function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was no difference in the success rate of BZD discontinuation between the control and experimental groups in this case [72].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [72]
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
(1987) · PubMed · Cited by 2,657
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
Physical activity and risk of cognitive impairment and dementia in elderly persons
Laurin, D., Verreault, R., Lindsay, J., MacPherson, K., & Rockwood, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.498 · Cited by 1,561 · cited 1×
“Regular physical activity was categorized as none, low, moderate, and high.(24) Nonsteroidal antiinflammatory drugs (NSAIDs) were coded as user or nonuser.”
BackgroundSelf-citationBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Benzodiazepine use and risk of dementia: prospective population based study
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.-F., Peres, K., Kurth, T., & Pariente, A. (2012) · BMJ · doi:10.1136/bmj.e6231 · Cited by 436
Martin, P., Tamblyn, R., Benedetti, A., Ahmed, S., & Tannenbaum, C. (2018) · JAMA · doi:10.1001/jama.2018.16131 · Cited by 401 · cited 1×
“Successful deprescribing interventions for benzodiazepines in older persons have recently been reported.(35,36)”
BackgroundPaterniti, S., Dufouil, C., & Alpérovitch, A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00009 · Cited by 313
Gray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233 · cited 1×
“performance among benzodiazepine users.(5,8,13-16) Most of these studies assessed cognitive function on the basis of scores obtained with the use of global screening instruments and neuropsychological test batteries.”
BackgroundBenzodiazepine use and cognitive decline in the elderly
Picton, J. D., Marino, A. B., & Nealy, K. L. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160381 · Cited by 203 · cited 1×
“A clinical review reported that the associations were strongest for longer-acting benzodiazepines, longer durations of use, and earlier rather than later exposure.(12) An increasing number of longitudinal studies have focused on the relationship between benzodiazepine use and cognitive decline in older people.”
BackgroundWu, C., Wang, S.-C., Chang, I., & Lin, K. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181a65210 · Cited by 166
Benzodiazepine use and risk of dementiaA nested case–control study
Lagnaoui, R., Bégaud, B., MOORE, N., Chaslerie, A., FOURRIER, A., Letenneur, L., Dartigues, J., & Moride, Y. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00453-x · Cited by 152
Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS)
Gallacher, J., Elwood, P., Pickering, J., Bayer, A., Fish, M., & Ben-Shlomo, Y. (2012) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2011-200314 · Cited by 151 · cited 1×
“performance among benzodiazepine users.(5,8,13-16) Most of these studies assessed cognitive function on the basis of scores obtained with the use of global screening instruments and neuropsychological test batteries.”
BackgroundNonsteroidal anti‐inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease
Côté, S., Carmichael, P., Verreault, R., Lindsay, J., Lefebvre, J., & Laurin, D. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.012 · Cited by 122 · cited 1×
“Nonsteroidal antiinflammatory drugs (NSAIDs) were coded as user or nonuser.(25) Education was treated as a continuous variable.”
BackgroundSelf-citationBierman, E. J. M., Comijs, H. C., Gundy, C. M., Sonnenberg, C., Jonker, C., & Beekman, A. T. F. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1811 · Cited by 114
Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2015) · Drug Safety · doi:10.1007/s40264-015-0319-3 · Cited by 112
Effect of Benzodiazepine Discontinuation on Dementia Risk
Wu, C., Ting, T., Wang, S.-C., Chang, I., & Lin, K. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181e049ca · Cited by 99 · cited 1×
“Given the known neurocognitive adverse effects of benzodiazepines, older populations could be more at risk of showing precocious cognitive dysfunction or dementia with time.(3) To date, studies investigating the associations between benzodiazepine use and dementia have shown conflicting results.”
BackgroundHutchinson, M. A., Smith, P. F., & Darlington, C. L. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(96)00011-1 · Cited by 95
Benzodiazepine, psychotropic medication, and dementia: A population‐based cohort study
Shash, D., Kurth, T., Bertrand, M., Dufouil, C., Barberger‐Gateau, P., Berr, C., Ritchie, K., Dartigues, J., Bégaud, B., Alpérovitch, A., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.10.006 · Cited by 94
Mura, T., Proust‐Lima, C., Akbaraly, T. N., Amieva, H., Tzourio, C., Chevassus, H., Picot, M., Jacqmin‐Gadda, H., & Berr, C. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.004 · Cited by 82
Benzodiazepine impairment of perirhinal cortical plasticity and recognition memory
Wan, H., Warburton, E. C., Zhu, X. O., Koder, T. J., Park, Y., Aggleton, J. P., Cho, K., Bashir, Z. I., & Brown, M. W. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03688.x · Cited by 81 · cited 1×
“First, there is the possibility of a decrease in the number of benzodiazepine receptors(29,30); second, a reduction in the number of chloride channels in the GABA A receptor complex(29); and finally, alterations in synaptic plasticity and recognition memory.(31) Several limitations in our study should be taken into co…”
BackgroundLindsay, J., Sykes, E., McDowell, I., Verreault, R., & Laurin, D. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900202 · Cited by 76 · cited 5×
“The study methods and the diagnostic criteria of the second follow-up (CSHA-3) were similar to those used in CSHA-2, although the 3MS cut-point was set at 89/90 for the screening of CIND rather than dementia.(21) For the purpose of this study, we used DSM-IV criteria in CSHA-2 and CSHA-3.”
BackgroundMethodSelf-citationA. Köhler, C., F. Magalhaes, T., M.M.P. Oliveira, J., S. Alves, G., Knochel, C., Oertel-Knöchel, V., Pantel, J., & F. Carvalho, A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160502123129 · Cited by 64 · cited 1×
“From the clinical practice point of view, although our findings do not support clinical decision making, it remains important to know that older adults with CIND, which is close in definition to MCI, may present with behavioral and psychological symptoms of dementia leading to a benzodiazepine prescription.(32) Revers…”
ResultBiétry, F. A.-M., Pfeil, A. M., Reich, O., Schwenkglenks, M. M., & Meier, C. R. (2017) · CNS Drugs · doi:10.1007/s40263-016-0404-x · Cited by 61
Allard, J., Artero, S., & Ritchie, K. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.891 · Cited by 60
Cognitive Impairment, No Dementia: Concepts and Issues
Tuokko, H. A., Frerichs, R. J., & Kristjansson, B. (2001) · International Psychogeriatrics · doi:10.1017/s104161020200813x · Cited by 60 · cited 1×
“The concept of cognitive impairment– no dementia (CIND) has been defined in the Canadian Study of Health and Aging (CSHA) as a heterogeneous clinical entity encompassing cognitive impairments that could evolve into various psychiatric and neurological diseases, including dementia.(18) In contrast to MCI case definitio…”
BackgroundChanges in benzodiazepine receptors in alzheimer‐type dementia
Shimohama, S., Taniguchi, T., Fujiwara, M., & Kameyama, M. (1988) · Annals of Neurology · doi:10.1002/ana.410230419 · Cited by 59
The risk of cognitive impairment in older community-dwelling women after benzodiazepine use
Lagnaoui, R., Tournier, M., Moride, Y., Wolfson, C., Ducruet, T., Begaud, B., & Moore, N. (2008) · Age and Ageing · doi:10.1093/ageing/afn277 · Cited by 51 · cited 4×
“This broadening of the CIND definition was found to increase the prediction of dementia compared with other classifications of MCI.19 In this latter study, about 30% of CIND participants converted to dementia over a 5-year period in CSHA.”
BackgroundInfluentialUse of benzodiazepines, depressive symptoms and cognitive function in old age
van Vliet, P., van der Mast, R. C., van den Broek, M., Westendorp, R. G. J., & de Craen, A. J. M. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2143 · Cited by 51
Patterns of Cognitive Decline, Conversion Rates, and Predictive Validity for 3 Models of MCI
Ritchie, L. J., & Tuokko, H. (2010) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317510382286 · Cited by 45 · cited 2×
“This broadening of the CIND definition was found to increase the prediction of dementia compared with other classifications of MCI.19 In this latter study, about 30% of CIND participants converted to dementia over a 5-year period in CSHA.”
ResultShaw, J. C., Murphy, A. L., Turner, J. P., Gardner, D. M., Silvius, J. L., Bouck, Z., Gordon, D., & Tannenbaum, C. (2019) · Healthcare policy · doi:10.12927/hcpol.2019.25857 · Cited by 40 · cited 1×
“Successful deprescribing interventions for benzodiazepines in older persons have recently been reported.(35,36)”
Background
Research works printed but not linked: 4
- 10.1002/ana22362 · doi:10.1002/ana22362
- Teng EL, 1987, J Clin Psychiatry, 48, 314
- WHO Collaborating Centre for Drug Statistics Methodology, 2015, Guidelines for ATC Classification and DDD Assignment 2016
- Hogan DB, 2003, Can J Clin Pharmacol, 10, 72
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
Promoting Successful Cognitive Aging: A Ten-Year Update
Krivanek, T. J., Gale, S. A., McFeeley, B. M., Nicastri, C. M., & Daffner, K. R. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201462 · Cited by 172
Ma, T., Wang, Z., Qin, X. S., Ju, C., Lau, W. C. Y., Man, K. K. C., Castle, D. J., Chang, W. C., Chan, A. Y. L., Cheung, E. C. L., et al. (2023) · SLEEP · doi:10.1093/sleep/zsad124 · Cited by 82
“M Moreover, increased risks of some adverse outcomes, including cognitive decline 22,23 , Alzheimer’s disease 24 and injury 25,26 were found in older adults with a history of BZDs and Z-drugs use. a Based on existing evidence, a consensus was found that the consumption of BZDs and Z-drugs increased…”
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Cacabelos, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093059 · Cited by 66
Anesthetic Considerations for Patients on Psychotropic Drug Therapies
Harbell, M. W., Dumitrascu, C., Bettini, L. M., Yu, S., Thiele, C. M., & Koyyalamudi, V. (2021) · Neurology International · doi:10.3390/neurolint13040062 · Cited by 64
“Given the high risk of cognitive impairment with benzodiazepine use in the elderly, its use should be avoided in those individuals older than 65 years of age [60].”
Background
Metadata
- Authors
- Nafti, M., Sirois, C., Kröger, E., Carmichael, P.-H., & Laurin, D.
- Affiliations
- Université Laval (CA)
- Centre de recherche du CHU de Québec-Université Laval (CA)
- Corresponding author
- Laurin, Danielle
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2019-10-09
- Volume
- 54
- Issue
- 3
- Pages
- 219-225
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2979645617
- Cited by
- 73
- References
- 32
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 12 · 2023: 16 · 2022: 8 · 2021: 12 · 2020: 6 · 2019: 1
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Corpus Université Laval (Université Laval) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Intensive Care Unit Cognitive Disorders
- Keywords
- benzodiazepines, cognitive impairment without dementia, dementia, Alzheimer's disease, cognitive decline, older adults, sex differences, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Benzodiazepines, Canada, Cognition, Dementia, Female, Humans, Male, Surveys and Questionnaires, Risk Factors, Sex Characteristics, Comorbidity, Proportional Hazards Models, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.